Piper Jaffray Reiterates Overweight Rating for Fluidigm (FLDM)
Fluidigm (NASDAQ:FLDM)‘s stock had its “overweight” rating restated by analysts at Piper Jaffray in a research report issued to clients and investors on Tuesday, Analyst Ratings News reports. They currently have a $50.00 price target on the stock. Piper Jaffray’s price target would suggest a potential upside of 28.04% from the company’s current price.
Fluidigm (NASDAQ:FLDM) traded down 15.03% during mid-day trading on Tuesday, hitting $33.18. 1,446,304 shares of the company’s stock traded hands. Fluidigm has a 52 week low of $15.72 and a 52 week high of $49.46. The stock has a 50-day moving average of $40. and a 200-day moving average of $38.11. The company’s market cap is $924.8 million.
Fluidigm (NASDAQ:FLDM) last released its earnings data on Monday, May 5th. The company reported ($0.57) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.26. The company had revenue of $25.70 million for the quarter, compared to the consensus estimate of $22.91 million. Fluidigm’s revenue was up 77.2% compared to the same quarter last year. Analysts expect that Fluidigm will post $-0.97 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Maxim Group cut their price target on shares of Fluidigm from $65.00 to $52.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Fluidigm from $52.00 to $48.00 in a research note on Tuesday. Finally, analysts at Mizuho upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a research note on Tuesday, April 22nd. They now have a $50.00 price target on the stock, up previously from $43.00. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Fluidigm currently has a consensus rating of “Buy” and an average target price of $44.76.
Fluidigm Corporation (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems such as single-cell genomics, applied genotyping and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.